Sort
82,697 grants matching “vaccine development”
Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products.
$2,000,000Hiiti Sillo · World Health Organization · U01 · FY2022 · FD
Adjuvant Comparison and Characterization (HIV)
$1,999,999Bali Pulendran · Stanford University · N01 · FY2024 · AI
EFRI DCheM: Distributed Ribonucleic Acid (RNA) Manufacturing via Continuous Enzymatic Reaction and Separation in Biphasic Liquid Media
$1,999,998Daeyeon Lee · University Of Pennsylvania · · FY2021 · ENG
CNT-VECTORED DELIVERY OF MRNA FOR HIV-VACCINES
$1,999,997Yang Xu · Luna Innovations, Inc. · N44 · FY2019 · AI
A Multifunctional Point of- Care Platform to Differentiate HIV Infection from Vaccine Induced Seropositivity
$1,999,995Ranier Ng · Baebies, Inc. · N43 · FY2025 · AI
SUPPORT SERVICES FOR HIV AIDS CLINICAL TRIAL NETWORKS
$1,999,984Barbara Driver · Westat, Inc. · N01 · FY2025 · HD
A Randomized Study of Exclusion Criteria in a University Population
$1,999,963Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2011 · CK
Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
$1,999,909Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2022 · IP
Design and Engineering of VesiVax HIV Immunogen Formulations
$1,999,866Samon Ho · Molecular Express, Inc. · N44 · FY2024 · AI
Cellular & Molecular Defects in Human B Cell Development
$1,999,734Charlotte Cunningham-Rundles · Icahn School Of Medicine At Mount Sinai · P01 · FY2011 · AI
Protection against Mucosal SIV Challenge by Adeno-Associated Virus Delivery of Env-Specific Antibodies
$1,999,460Maria Ferrari · Bioqual, Inc. · N01 · FY2023 · AI
Anthrax Immune Globulin to Prevent & Treat Anthrax: Advanced Product Development
$1,998,521Gary S Nabors · Emergent Product Development Gaithersbur · U01 · FY2006 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$1,998,462Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Immune modulation by highly virulent clinical isolates of M.tuberculosis
$1,998,452Diane Joyce Ordway · Colorado State University · DP2 · FY2009 · OD
Immunogen Design for Specific BCR Activation
$1,997,824Leonidas A Stamatatos · Fred Hutchinson Cancer Research Center · U19 · FY2020 · AI
Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention
$1,997,089Robert Rodick · Vxbiosciences, Inc. · R01 · FY2023 · AI
Radiation Survivor Core
$1,997,077J. Mark Cline · Duke University · U19 · FY2017 · AI
NIAID Preclinical Development Support
$1,996,916William Coale · Advanced Bioscience Laboratories, Inc. · N01 · FY2011 · AI
Genetic variants associated with smallpox vaccine immune response heterogeneity
$1,996,839Gregory Poland · Mayo Clinic Rochester · N01 · FY2013 · AI
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,996,220Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2025 · IP
HIV VACCINE TRIAL CLINICAL UNIT
$1,996,036Harvard University (Medical School) · U01 · FY2000 · AI
Center for Biologically Inspired Nano-scaffolds for Mitigating Chlamydia trachomatis Pathogenesis
$1,995,618Matthew Adrian Coleman · University Of Calif-Lawrnc Lvrmr Nat Lab · U19 · FY2021 · AI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity
$1,995,375Ignacio E. Sanz · Emory University · U54 · FY2022 · CA
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)
$1,995,256Eugene M. Oltz · Ohio State University · U54 · FY2022 · CA
LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS
$1,995,113Harvard University (Medical School) · P01 · FY2004 · AI